Table 5.
What issues do you take into consideration while preferring the generics?
| Pharmacist | Prescriber | Patient | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Agree/ strongly agree N (%) |
Unsure/ No idea N (%) |
Disagree/ strongly disagree N (%) |
Agree/ strongly agree N (%) |
Unsure/ No idea N (%) |
Disagree/ strongly disagree N (%) |
Agree/ strongly agree N (%) |
Unsure/ No idea N (%) |
Disagree/ strongly disagree N (%) |
|
| Manifacturer | 46 (82.1) | 5 (8,9) | 5 (8.9) | 28 (70) | 4 (10) | 8 (20) | 57 (56.4) | 7 (7) | 37 (36.6) |
| Place of production | 26 (49.1) | 10 (18.9) | 17 (32) | 20 (51) | 3 (8) | 16 (41) | 39 (38.6) | 12 (11.9) | 50 (49.5) |
| Cost | 45 (81.8) | 4 (7.3) | 6 (10.9) | 36 (92) | - (0) | 3 (8) | 84 (83.2) | 3 (3) | 14 (13.8) |
| Efficacy | 53 (96.4) | - | 2 (3.6) | 37 (92) | 1 (3) | 2 (5) | 92 (91.1) | 1 (1) | 8 (7.9) |
| Side effects | 41 (82.0) | 5 (10.0) | 3 (8.0) | 36 (90) | - (0) | 4 (10) | 90 (89.1) | 1 (1) | 10 (9.9) |
| Physical properties (taste, odour, colour, pharmaceutical form etc) | 30 (61.3) | 4 (8.2) | 15 (30.6) | 27 (68) | 4 (10) | 9 (22) | 62 (61.4) | 9 (8.9) | 30 (29.7) |
| Date of launching in the market | 27 (51.9) | 8 (15.4) | 17 (32.7) | 19 (50) | 7 (18) | 12 (32) | 58 (57.4) | 11 (10.9) | 32 (31.7) |